Aclaris completes enrollment in phase 2 atopic dermatitis trial

March 18, 2026 6:55 AM

Aclaris Therapeutics Inc. (NASDAQ: ACRS) completed patient enrollment in its Phase 2 trial of bosakitug (ATI-045) for patients with moderate-to-severe ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found